5 completed, 5 unknown. 5 Phase 3, 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Unknown 3, Completed 2 |
| Phase 1 | 4 | Completed 2, Unknown 2 |
| Phase 2 | 4 | Completed 2, Unknown 2 |
Follow COVID-19 Prevention: new trials by email Literature Review of COVID-19 Prevention trials Research Report on COVID-19 Prevention
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray Q-Griffithsin 3.0, Q-Griffithsin 6.0 - COVID-19 Prevention | Phase 1 | Unknown | Kenneth Palmer | 24 | 2022-06-15 | 2022-07-05 |
| PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray Q-Griffithsin, Placebo - COVID-19 Prevention | Phase 1 | Completed | Kenneth Palmer | 18 | 2021-11-11 | 2022-04-29 |
| A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults Ad26.COV2.S, Placebo, Influenza Vaccine - COVID-19 Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 861 | 2021-11-02 | 2025-05-25 |
| A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) Ad26.COV2.S - COVID-19 Prevention | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 51 | 2021-08-27 | 2025-05-25 |
| A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults Ad26.COV2.S - COVID-19 Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 1609 | 2021-06-18 | 2025-02-04 |
| Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 Hydroxychloroquine (HCQ), Standard care, Placebo - Covid19, COVID-19 Prevention | Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 1000 | 2021-03-22 | 2021-06-11 |
| Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Sputnik Light, Placebo - COVID-19 Prevention | Phase 3 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 6000 | 2021-02-19 | 2021-02-21 |
| An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine Sputnik Light - COVID-19 Prevention | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 110 | 2021-01-15 | 2021-02-02 |
| Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection Gam-COVID-Vac, Placebo - COVID-19 Prevention | Phase 2 / Phase 3 | Unknown | Dr. Reddy's Laboratories Limited | 1600 | 2020-11-30 | 2021-06-02 |
| A Study of Ad26.COV2.S in Adults (COVID-19) Ad26.COV2.S, Placebo - Covid-19 Prevention | Phase 1 / Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 1085 | 2020-07-15 | 2025-02-04 |
COVID-19 (6) · Coronavirus Infections (1)
Coronaviridae Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · Pneumonia, Viral (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Virus Diseases (6) · Coronavirus Infections (5)
Ad26COVS1 (4) · Gam-COVID-Vac vaccine (1) · Hydroxychloroquine (1) · Influenza Vaccines (1) · Standard of Care (1) · q-griffithsin (1)
Janssen Vaccines & Prevention B.V. (4) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (2) · Kenneth Palmer (2) · Dr. Reddy's Laboratories Limited (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1)
United States (6) · Belgium (2) · Brazil (2) · India (2) · Poland (2) · Russia (2) · South Africa (2) · Germany (1)
PMID 37699630, PMID 33083026, PMID 33440088, PMID 33704352, PMID 35667914, PMID 39866854, PMID 40808283